XP1000 RF Therapy on Waist Circumference Reduction

Overview

This study was designed to demonstrate safety and efficacy of the XP1000 RF for non-invasive temporary reduction of waist circumference by disruption of adipocyte cells.

Full Title of Study: “Effect of the XP1000 RF Therapy on Waist Circumference Reduction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 2015

Detailed Description

This study is a prospective, double-blinded, randomized, two-arm sham-controlled study of circumferential waist reduction following 4 treatment sessions delivered once a week over a 4-week period. The objective of the study is to demonstrate the effectiveness of the treatment after 30-day and 90-day Follow Up in achieving waist circumference reduction of ≥3 cm across the waist line relative to the base line assessment and their mean waist circumferential reduction is ≥1 cm than the average circumferential reduction of sham group.

Interventions

  • Device: XP1000 RF
    • Treatment of adipose tissue within the fat layer with XP1000 RF.
  • Device: sham XP1000 RF
    • Treatment of adipose tissue within the fat layer with XP1000 RF.

Arms, Groups and Cohorts

  • Experimental: XP1000 RF group
    • Subjects in the XP1000 RF group will be treated with the XP1000 RF device.
  • Sham Comparator: Sham group
    • Subjects in the Sham group will be treated with the sham XP1000 RF device.

Clinical Trial Outcome Measures

Primary Measures

  • Waist Circumferential reduction
    • Time Frame: 30 days follow follow up after 4 once-a-week treatments
    • The primary efficacy outcome measure is set to be a minimum of 80% of subjects in the XP1000 RF group at 30-day follow up evaluation to show waist circumference reduction of ≥3 cm across the waist line relative to the base line assessment and their mean waist circumferential reduction is ≥1 cm than the average circumferential reduction of Sham group.

Secondary Measures

  • Adverse Events
    • Time Frame: 1 month follow up
    • Absence of adverse events (AE) associated with the treatment procedure. Safety evaluations of skin reaction in the treatment area would be conducted at every treatment and follow up visits
  • Adverse Events
    • Time Frame: 3 months follow up
    • Absence of adverse events (AE) associated with the treatment procedure. Safety evaluations of skin reaction in the treatment area would be conducted at every treatment and follow up visits

Participating in This Clinical Trial

Inclusion Criteria

  • Body Mass Index (BMI) of 20 to 35 kg/m2. – Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation. – Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting significant change in either direction during study participation. Exclusion Criteria:

  • Implanted electronic device such as a cardiac pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, etc. – Diabetics dependent on insulin or oral hypoglycemic medications – Known cardiovascular disease such as arrhythmias, congestive heart failure – Cardiac surgeries such as cardiac bypass, heart transplant surgery, pacemakers. – Prior surgical interventions for body sculpting of abdomen such as liposuction – Medical, physical or other contraindications for body sculpting/ weight loss – Current use of medication known to affect weight levels and/or cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent – Any medical condition known to affect weight levels and/or to cause bloating or swelling – Active infection, wound or other external trauma to the area to be treated – Pregnant, breast feeding, or planning pregnant before the end of the study – Serious mental health illness – Active or recurrent cancer or current chemotherapy and/or radiation treatment – Negative affection to heat

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • BTL Industries Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Radina Denkova, MD, Principal Investigator, Aesthe Beauty Clinic

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.